Sorry, you need to enable JavaScript to visit this website.

A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel Group Study to Evaluate Safety, Tolerability and Pharmacodynamics of PF-06835919 Administered Daily for 16 Weeks in Adults With Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus on Metformin.

Category & Conditions: Diabetes and Metabolic Disorders
Medicine: PF-06835919
ClinicalTrials.gov Identifier (NCT): NCT03969719
Protocol ID: C1061011
    Share
PrintDownload
Open Plain Language Summary Result: Click here